Worth reading
46Recurring
Scored from 3 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
90000
Dollars (increase in capital)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Intended allottee
Investment in a U.S. subsidiary wholly owned by Kringle Pharma,Inc.
Payment date
April 2026 (scheduled)
Most recent equity financing
November 2025: $10,000 in capital at the time the U.S. subsidiary was established (as stated in the document)
Impact on Business Performance
The impact on the earnings forecast for the fiscal year ending September 2026 is expected to be minor at this time.
| Item | Details |
|---|---|
| Payment date | April 2026 (scheduled) |
| Intended allottee | Investment in a U.S. subsidiary wholly owned by Kringle Pharma,Inc. |
| Most recent equity financing | November 2025: $10,000 in capital at the time the U.S. subsidiary was established (as stated in the document) |
| Impact on Business Performance | The impact on the earnings forecast for the fiscal year ending September 2026 is expected to be minor at this time. |
Items this document does not state (24)
Type of issuance or disposalNumber of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offering
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To stabilize the U.S. subsidiary's financial foundation and further accelerate and advance the development of a drug for the acute-phase treatment of spinal cord injury in the United States. The subsidiary is pursuing activities to obtain grants from the U.S. government and public institutions, preparing for an IND (Investigational New Drug) application, and engaging in business development and partnering activities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.